Claims for Patent: 7,811,773

Summary for Patent: 7,811,773

Title:	Analytical method
Abstract:	The instant invention describes an analytical assay to accurately measure an analyte in the presence of an interfering substance.
Inventor(s):	Ralph; Peter (Orinda, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	11/863,138
Patent Claims:	1. A kit for accurately determining the total amount of an anti-HER2 antibody in serum or plasma in the presence of HER2 extracellular domain, comprising: a) a solid surface coated with a first antibody recognizing free anti-HER2 antibody and a second antibody recognizing said HER2 extracellular domain when bound to said anti-HER2 antibody; and (b) a detectably labeled secondary antibody recognizing said anti-HER2 antibody at an epitope which is different from that recognized by said first antibody and also different from the epitope recognized by said HER2 extracellular domain. 2. The kit of claim 1, wherein said solid surface is in a configuration of a test tube, a well, a bead, a rod, or a strip. 3. The kit of claim 2, wherein said configured solid surface is glass, plastic, or paper. 4. The kit of claim 3, wherein said plastic is polystyrene or polyacrylate. 5. The kit of claim 1, wherein said anti-HER2 antibody is a murine monoclonal antibody. 6. The kit of claim 5, wherein said murine anti-HER2 monoclonal antibody is 4D5. 7. The kit of claim 6, wherein said anti-HER2 murine monoclonal antibody is a humanized version of recombinant 4D5 antibody. 8. The kit of claim 7, wherein said humanized version of recombinant 4D5 anti-HER2 antibody is trastuzumab. 9. The kit of claim 1, wherein said first antibody recognizes trastuzumab, and does not significantly cross-react with human IgG, and said second antibody against HER2 extracellular domain is a polyclonal or a monoclonal antibody. 10. The kit of claim 9, wherein said anti-trastuzumab antibody is a monoclonal antibody or a fragment derived therefrom, and said monoclonal antibody against HER extracellular domain is 7C2 (ATCC No. HB-12215). 11. The kit of claim 1, wherein said serum or plasma is derived from a cancer patient undergoing anti-HER2 therapy. 12. The kit of claim 11, wherein said cancer is breast cancer overexpressing HER2. 13. A microtiter plate for accurately determining the amount of an anti-HER2 antibody in serum or plasma in the presence of HER2 extracellular domain, comprising: (a) a first antibody recognizing free anti-HER2 antibody and a second antibody recognizing said HER2 ECD when bound to said anti-HER2 antibody; and (b) wherein said first and said second antibodies are coated on the surface of said microtiter plate.

Details for Patent 7,811,773

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2020-08-15
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2020-08-15
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2020-08-15